

## Phase II trial of androgen deprivation therapy (ADT) and pembrolizumab for advanced stage androgen receptor-positive salivary gland carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111

**Status:** Recruiting

### Eligibility Criteria

**Age:** 18 years and over

This study is NOT accepting healthy

**Healthy Volunteers:** volunteers

#### Inclusion Criteria:

- at least 18 years old - locally advanced, recurrent, or metastatic salivary gland carcinoma that is not amenable to curative surgery or radiation - tumor is androgen receptor-positive - unable to do physically strenuous activity but can walk and is able to do work of a light nature, such as house work or office work - prior chemotherapy, radiation, or surgery as part of curative intent therapy are allowed - any number of prior lines of systemic therapy are permitted as long as it did not include anti-androgen therapy or immune checkpoint blockade - men and women of child bearing age must agree to use contraception during the treatment period and for at least 8 months after the last dose of study treatment - contact study staff for additional requirements

#### Exclusion Criteria:

- received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX40, CD137) - received prior androgen deprivation therapy - pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the first visit through 120 days after the last dose of trial treatment. - additional cancer that is progressing or has required active treatment within the past 2 years - contact study staff for additional exclusion criteria

### Conditions & Interventions

#### Conditions:

Cancer

#### Keywords:

Salivary Gland Carcinoma, Clinics and Surgery Center (CSC)

### More Information

**Description:** We are looking at the effectiveness of adding an immunotherapy drug, pembrolizumab, to usual treatment for people who have salivary gland cancer that can't be treated with surgery or radiation. The cancer must be androgen receptor positive.

**Contact(s):** Manish Patel - patel069@umn.edu

**Principal Investigator:** Manish Patel

**Phase:** PHASE2

**IRB Number:** STUDY00004710

**System ID:** 20371

Thank you for choosing StudyFinder. Please visit <http://studyfinderstaging.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.